Literature DB >> 12728117

Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta.

Kathleen Montpetit1, Horacio Plotkin, Frank Rauch, Nathalie Bilodeau, Suzanne Cloutier, Mary Rabzel, Francis H Glorieux.   

Abstract

OBJECTIVE: To examine changes in grip force during pamidronate therapy in children and adolescents with severe osteogenesis imperfecta (OI).
METHODS: Maximal isometric grip force of the nondominant hand was prospectively determined in 42 patients (age at the start of the study: 7.3-15.9 years; 18 girls) with severe forms of OI. Patients were treated with intravenous pamidronate infusions given in 4 monthly cycles, each cycle consisting of 3 infusions (1 mg pamidronate/kg body wt) on 3 successive days.
RESULTS: At the start of pamidronate therapy, grip force was low compared with age-specific reference data (age z score mean +/- standard deviation: -2.7 +/- 2.1) but was normal for weight (weight z score: -0.1 +/- 1.8). Four months after the first pamidronate infusion cycle, grip force had increased significantly, whether related to age (age z score: -2.0 +/- 1.8) or to weight (weight z score: 0.6 +/- 1.5). At 2 years after the start of therapy, grip force z scores were not significantly different from the 4-month results.
CONCLUSIONS: Maximal isometric grip force markedly increases after a single cycle of intravenous pamidronate in children with severe forms of OI, and this gain in grip force is maintained for at least 2 years.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12728117     DOI: 10.1542/peds.111.5.e601

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  15 in total

Review 1.  Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.

Authors:  J Thornton; D M Ashcroft; M Z Mughal; R A Elliott; T W O'Neill; D Symmons
Journal:  Arch Dis Child       Date:  2006-05-11       Impact factor: 3.791

Review 2.  Bisphosphonate treatment of bone disease.

Authors:  N J Shaw; N J Bishop
Journal:  Arch Dis Child       Date:  2005-05       Impact factor: 3.791

Review 3.  Osteogenesis imperfecta: new treatment options.

Authors:  Guillaume Chevrel; Rolando Cimaz
Journal:  Curr Rheumatol Rep       Date:  2006-12       Impact factor: 4.592

4.  Muscle weakness as presenting symptom of osteogenesis imperfecta.

Authors:  Annemieke M Boot; Rene F M de Coo; Gerard Pals; Sabine M P F de Muinck Keizer-Schrama
Journal:  Eur J Pediatr       Date:  2006-03-14       Impact factor: 3.183

Review 5.  Muscle-Bone Interactions in Pediatric Bone Diseases.

Authors:  Louis-Nicolas Veilleux; Frank Rauch
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

6.  The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta.

Authors:  Demetris Delos; Xu Yang; Benjamin F Ricciardi; Elizabeth R Myers; Mathias P G Bostrom; Nancy Pleshko Camacho
Journal:  J Orthop Res       Date:  2008-02       Impact factor: 3.494

Review 7.  Osteogenesis Imperfecta: update on presentation and management.

Authors:  Moira S Cheung; Francis H Glorieux
Journal:  Rev Endocr Metab Disord       Date:  2008-04-11       Impact factor: 6.514

Review 8.  Bone disease in pediatric rheumatologic disorders.

Authors:  Jon M Burnham; Mary B Leonard
Journal:  Curr Rheumatol Rep       Date:  2004-02       Impact factor: 4.592

9.  Decrease in outpatient department visits and operative interventions due to bisphosphonates in children with osteogenesis imperfecta.

Authors:  F de Graaff; W Verra; J E H Pruijs; R J B Sakkers
Journal:  J Child Orthop       Date:  2011-01-25       Impact factor: 1.548

10.  The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta.

Authors:  Ingmar Ipach; Torsten Kluba; Petra Wolf; Bertram Pontz; Falk Mittag
Journal:  Orthop Rev (Pavia)       Date:  2012-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.